Rybrevant 350mg Injection

About

Amivantamab is a first-in-class bispecific antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptors. It is specifically designed to target and remove cancer cells that harbor activating and resistance EGFR mutations, including exon 20 insertion mutations, as well as MET mutations and amplifications. By binding simultaneously to both EGFR and MET, amivantamab blocks ligand binding, promotes the degradation of these receptors, and mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against tumor cells. This innovative dual-targeting mechanism offers a novel and crucial therapeutic approach for treating specific subsets of non-small cell lung cancer, particularly those with EGFR exon 20 insertion mutations, which are often resistant to standard EGFR tyrosine kinase inhibitors, providing a much-needed option for these challenging cases.

Uses

• Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
• Specifically for NSCLC with EGFR exon 20 insertion mutations.
• Used after progression on platinum-based chemotherapy.
• Targets both EGFR and MET pathways.

Directions For Use

Administered intravenously by a healthcare professional. The dosage is weight-based and given weekly for the first 4 weeks, then every two weeks.

Benefits

• First-in-class bispecific antibody targeting EGFR and MET.
• Effective for NSCLC with EGFR exon 20 insertion mutations.
• Provides a new treatment option for a difficult-to-treat subset of NSCLC.
• Induces tumor cell degradation and immune-mediated killing.
• Offers a targeted approach for specific genetic mutations.
• May improve progression-free survival in eligible patients.

Side Effects

• Infusion-related reactions
• Rash
• Paronychia (nail inflammation)
• Stomatitis
• Fatigue
• Edema
• Constipation
• Nausea
• Diarrhea
• Pruritus
• Hypoalbuminemia
• Corneal toxicity

Safety Measures

• Alcohol - No specific interaction with alcohol is known; however, general health recommendations apply during cancer treatment.
• Pregnancy - Amivantamab can cause fetal harm. It is not recommended during pregnancy, and effective contraception should be used during treatment and for 3 months after the last dose.
• Breastfeeding - It is unknown if amivantamab is excreted in human milk. Due to potential serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for 3 months after the last dose.
• Liver - Use with caution in patients with severe hepatic impairment; however, no specific dose adjustments are generally required based on liver function alone.
• Kidney - No specific dose adjustments are typically required for renal impairment, but caution is advised, and monitoring may be considered.
• Lung - Interstitial lung disease (ILD) or pneumonitis has been reported. Monitor patients for new or worsening respiratory symptoms and discontinue if ILD is confirmed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.